The pharmaceutical industry is on the move: already in the EU every third new medicine requires special refrigeration

Instead of chemical drugs, biological drugs represent an increasing proportion in the pharmaceutical industry. Such preparations consist of large and complex molecules derived from living organisms, primarily proteins. Biosimilar medicines are medicinal products that are fundamentally similar to an already authorized biological medicine, including its active ingredient. In the case of biological medicines, the product is the process itself, because the method of production plays an important role in the production of these medicinal products, due to the characteristics of the living cells used during production.

“The price level of biotechnological products is generally higher than that of traditional chemically produced small-molecule drugs, given the higher research and development costs, the increased safety requirements due to the complexity at the molecular level, and the related higher production costs. In its industry, the pharmaceutical industry, the importance of biotechnology products is also outstanding at the world level: in the USA, 28% of products granted marketing authorization after 2010, and in the European Union, every third new medicine is of biotechnology origin.

– said Luczek Balázs, deputy director of Reflex Transport and Transportation Kft.